FYREMADEL (ganirelix acetate) by Fosun Pharma is clinical pharmacology the pulsatile release of gnrh stimulates the synthesis and secretion of luteinizing hormone (lh) and follicle-stimulating hormone (fsh). First approved in 2018.
Drug data last refreshed 3d ago
CLINICAL PHARMACOLOGY The pulsatile release of GnRH stimulates the synthesis and secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). The frequency of LH pulses in the mid and late follicular phase is approximately 1 pulse per hour. These pulses can be detected as transient…
Worked on FYREMADEL at Fosun Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.